A new approach to treating severe hypoglycemia

Enject Inc.
GlucaPen® is not yet approved and is still in development.

See our "News & Press" page for articles.

We've finished the prototype and are working with the FDA on development of testing requirements. GlucaPen® will inject glucagon to treat Severe Hypoglycemia (SH)...a potentially life threatening medical emergency that occurs in insulin using Type 1 and Type 2 diabetics.

On this web site you will be able to learn more about severe hypoglycemia, our solution GlucaPen®
and the team responsible for its development. Please contact us with any questions, comments or suggestions.

If you want to be kept updated on the latest developments on
GlucaPen® please visit our News and Press page and sign-up for our newsletter.

Enject Inc.
glucapen@enject.com
360-666-2562